FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| | ·^ | | |
|--|----|------|--|
| | | | |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1(c). Se | ee Instruction 1 | 0. | | | | | | | | | | | | | | | | | | | |
|--|--|--|-----------------|---|---|--|---|----------------------------------|--|--------------------|------------------------------|--|---------------------|---|--|--|--|--|-----------------|---------|--|
| Name and Address of Reporting Person* | | | | | | 2. Issuer Name and Ticker or Trading Symbol PROCEPT BioRobotics Corp. [PRCT] | | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | |
| Zadno Reza | | | | | PROCEPT BIOKODOUCS COTP [PRCT] | | | | | | | | | V | Direc | , | | 10% O | wner | | |
| (1,4) | (F:- | 4) (0 | A: -1 -11 | -> | | 2-461 | | 4 T | | : (84- | 41- /5 | D (M) | | - | 1 | Office | er (give title | | Other (: below) | specify | |
| (Last) (First) (Middle) C/O PROCEPT BIOROBOTICS CORPORATION | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/04/2024 | | | | | | | | | | | | | | | | |
| 150 BAYTECH DRIVE | | | | | | | | | | | | | | | | | | | | | |
| - Iso BATTBETT BICKYE | | | | | 4. I | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | | |
| (Street) | | | | | | | | | | | | | | _ine) ✓ Form filed by One Reporting Perso | | | | on | | | |
| SAN JOSE CA 95134 | | | | | | | | | | | | | | | | Form filed by More than One Reporting | | | | | |
| (City) | (St | ate) (2 | Zip) | | | | | | | | | | | | | Person | | | | | |
| | | Table | I - I | Non-Deriva | itive | Secu | rities | s Ac | qui | red, C | Disp | osed o | f, or l | Benefic | cially | Own | ed | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye | | | ear) | 2A. Deemed Execution Date, if any (Month/Day/Year) | | е, | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an | | | d (A) or r. 3, 4 and | i 5) | 5. Amount of Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) | | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | (| | Ĺ | Code | v | Amo | ount | (A) or (D) | Price | | | | (Inst | | (Instr. 4) | | |
| Common Stock 12/04/20. | | | | 12/04/202 | 4 | 1 | | | S ⁽¹⁾ | | 5 | 5,300 | D | \$96.1532(2) | | 173,885 | | | D | | |
| Common Stock 12/04/2024 | | | | 4 | | | | S ⁽¹⁾ | | 13 | 3,762 | D | \$97.0 | 11(3) | 160,123 | | | D | | | |
| Common Stock 12/04/2024 | | | | 4 | | | | S ⁽¹⁾ | | 5 | 5,126 | D | \$98.08 | \$98.0897(4) | | 154,997 | | D | | | |
| Common Stock 12/04/2024 | | | 4 | | | S ⁽¹⁾ | | 2 | 2,235 | D | \$99.04 | 122(5) | 15 | 152,762 | | D | | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Execution Date, | | | ransaction of ode (Instr. Derivative | | Expiration Date (Month/Day/Year) | | | Amo Secu Unde Deriv | , | Deri Sec (Ins | rice of ivative urity tr. 5) | 9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | e s ally g | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | Code | e V | (A) | (D) | Date D) Exercisa | | | Expiration Date | Title | Amount or Number of Shares | r | | | | | | | | |

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$95.65 to \$96.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote

- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$96.65 to \$97.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$97.66 to \$98.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$98.97 to \$99.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Remarks:

/s/ Jonathan Stone, Attorneyin-Fact for Reza Zadno, Ph.D.

12/06/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.